Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
1.53
USD
|
+2.68%
|
|
+13.33%
|
+34.21%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,546
|
300.3
|
165.8
|
39.16
|
31.81
|
42.8
|
-
|
-
|
Enterprise Value (EV)
1 |
1,216
|
20.35
|
165.8
|
39.16
|
31.81
|
42.8
|
42.8
|
42.8
|
P/E ratio
|
-26.2
x
|
-8.2
x
|
-2.39
x
|
-0.52
x
|
-0.51
x
|
-0.87
x
|
-0.91
x
|
-1.57
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
244
x
|
13.4
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
244
x
|
13.4
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-44,428,598
x
|
-7,942,674
x
|
-2,607,519
x
|
-545,547
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-39.6
x
|
-
|
-2.78
x
|
-
|
-
|
-0.89
x
|
-0.68
x
|
-0.59
x
|
FCF Yield
|
-2.52%
|
-
|
-36%
|
-
|
-
|
-112%
|
-147%
|
-171%
|
Price to Book
|
2.75
x
|
1.02
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
27,443
|
27,553
|
27,626
|
27,775
|
27,903
|
27,973
|
-
|
-
|
Reference price
2 |
56.33
|
10.90
|
6.000
|
1.410
|
1.140
|
1.530
|
1.530
|
1.530
|
Announcement Date
|
3/12/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.347
|
22.38
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-34.79
|
-37.81
|
-63.57
|
-71.78
|
-
|
-
|
-
|
-
|
EBIT
1 |
-37.48
|
-41.22
|
-70.76
|
-75.91
|
-67.64
|
-52.84
|
-52.71
|
-62.07
|
Operating Margin
|
-590.55%
|
-184.22%
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-33.74
|
-36.6
|
-69.39
|
-74.73
|
-62.72
|
-47.1
|
-49.91
|
-59.28
|
Net income
1 |
-33.74
|
-36.6
|
-69.39
|
-74.73
|
-62.72
|
-49.02
|
-50.31
|
-59.28
|
Net margin
|
-531.54%
|
-163.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.150
|
-1.330
|
-2.510
|
-2.690
|
-2.250
|
-1.750
|
-1.685
|
-0.9750
|
Free Cash Flow
1 |
-38.99
|
-
|
-59.6
|
-
|
-
|
-48
|
-63
|
-73
|
FCF margin
|
-614.37%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.07
|
-20.77
|
-18.13
|
-19.24
|
-17.77
|
-17.07
|
-19.16
|
-15.62
|
-15.79
|
-15.76
|
-11.6
|
-11.45
|
-11.82
|
-11.88
|
-12.25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-16.94
|
-20.6
|
-17.92
|
-18.91
|
-17.3
|
-16.1
|
-17.86
|
-14.3
|
-14.47
|
-17.11
|
-10
|
-9.7
|
-10.3
|
-9.7
|
-10.55
|
Net income
1 |
-16.94
|
-20.6
|
-17.92
|
-18.91
|
-17.3
|
-16.1
|
-17.86
|
-14.3
|
-14.47
|
-17.11
|
-10.5
|
-10.38
|
-10.78
|
-11.22
|
-11.65
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6100
|
-0.7400
|
-0.6500
|
-0.6800
|
-0.6200
|
-0.5800
|
-0.6400
|
-0.5100
|
-0.5200
|
-0.6100
|
-0.3767
|
-0.3700
|
-0.3833
|
-0.3950
|
-0.4100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/4/23
|
8/3/23
|
11/2/23
|
3/21/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
330
|
280
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-39
|
-
|
-59.6
|
-
|
-
|
-48
|
-63
|
-73
|
ROE (net income / shareholders' equity)
|
-24.6%
|
-11.9%
|
-26.3%
|
-37.3%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
20.50
|
10.70
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.270
|
-1.630
|
-2.070
|
-1.940
|
-
|
-
|
-
|
-
|
Capex
1 |
3.37
|
7.13
|
2.36
|
-
|
-
|
1
|
1
|
1
|
Capex / Sales
|
53.11%
|
31.87%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
1.53
USD Average target price
5
USD Spread / Average Target +226.80% Consensus |
1st Jan change
|
Capi.
|
---|
| +34.21% | 42.8M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|